Nighttime short-acting beta-agonist (SABA) in asthma and COPD
W. Anderson (Aurora, United States of America), R. Gondalia (San Francisco, United States of America), H. Hoch (Aurora, United States of America), M. Barrett (San Francisco, United States of America), S. Szefler (Aurora, United States of America), D. Van Sickle (Madison, United States of America), D. Stempel (San Francisco, United States of America)
Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Anderson (Aurora, United States of America), R. Gondalia (San Francisco, United States of America), H. Hoch (Aurora, United States of America), M. Barrett (San Francisco, United States of America), S. Szefler (Aurora, United States of America), D. Van Sickle (Madison, United States of America), D. Stempel (San Francisco, United States of America). Nighttime short-acting beta-agonist (SABA) in asthma and COPD. 859
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: